Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr:7:e2200573.
doi: 10.1200/PO.22.00573.

Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials

Thomas B Karasic  1 , Jennifer R Eads  1 , Lipika Goyal  2
Affiliations
Review

Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials

Thomas B Karasic et al. JCO Precis Oncol. 2023 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Figures

FIG 1.
FIG 1.
New and emerging targets in cholangiocarcinoma. ARID1A, AT-rich interaction domain 1A; BAP1, BRCA1-associated protein 1; BRAF, v-raf murine sarcoma viral oncogene homolog B1; BRCA, breast cancer gene; ERK, extracellular signal-regulated kinase; FGFR2, fibroblast growth factor receptor 2; HCQ, hydroxychloroquine; HER2, human epidermal growth factor receptor 2; IDH, isocitrate dehydrogenase; KGDH, alpha ketoglutarate dehydrogenase; KRAS, Kirsten rat sarcoma virus; MDM2, mouse double minute 2; MEK, mitogen-activated protein kinase; NTRK, neurotrophic tropomyosin receptor kinase; PDH, pyruvate dehydrogenase; PK CK2, protein kinase CK2; RAF, rapidly accelerated fibrosarcoma; RAS, rat sarcoma virus; RET, rearranged during transfection; TGF-β1, transforming growth factor beta 1.
See this image and copyright information in PMC

References

    1. Yao KJ, Jabbour S, Parekh N, et al. Increasing mortality in the United States from cholangiocarcinoma: An analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 2016;16:117. - PMC - PubMed
    1. Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104–114. - PubMed
    1. Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol. 2020;72:95–103. - PubMed
    1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281. - PubMed
    1. Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015. - PubMed

Publication types